1 euptake inhibitors, and 1.2 (1.0 to 1.4) for trazodone.

2 er month, -0.71; 95% CI, -1.19 to -0.24) and trazodone (-0.60; 95% CI, -1.09 to -0.11).

3 tonin-reuptake inhibitors (612 subjects), or trazodone (304 subjects) or nonusers of antidepressants

4           Thus, in prion-diseased mice, both trazodone and dibenzoylmethane treatment restored memory

5 luoxetine, its metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpipera

6 acting on serotonin signalling pathways e.g. trazodone and lorcaserin.

7 iveness of a combination of serotoninergics, trazodone, and L-tryptophan, in our animal model of OSAH

8                               Topiramate and trazodone have limited evidence supporting efficacy for

9                 We identified two compounds, trazodone hydrochloride and dibenzoylmethane, which reve

10                                              Trazodone in particular, a licensed drug, should now be

11                                              Trazodone/ L-tryptophan dose-dependently reduced sleep f

12                                              Trazodone/L-tryptophan caused dose-dependent reductions

13 ssociation with receiving a prescription for trazodone (OR = 1.38, p = 0.04).

14                                     Further, trazodone reduced p-tau burden.

15 amine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine, and agomelatine.

16                                 Zolpidem and trazodone were the most widely prescribed initial sleep

17                                              Trazodone with L-tryptophan can treat sleep-disordered b